Overview

Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal Adenocarcinoma

Status:
Active, not recruiting

Trial end date:
2022-03-01

Target enrollment:

Participant gender:

Summary

Determine the efficacy of combination Gemcitabine and Docetaxel chemotherapy in the treatment of metastatic colorectal cancer with CHFR and/or Microsatellite Instability (MSI) phenotype.

Phase:

Phase 2

Details

Lead Sponsor:

Sidney Kimmel Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Treatments:

Docetaxel
Gemcitabine
Lenograstim